Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for ...

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at ... At the same time, the Dow lost 1.69%, and the tech-heavy Nasdaq lost 2.7%. The drugmaker's stock has climbed by 5.91% in the ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its last close.

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...

The latest CNBC CFO Council Survey found that 60% of CFOs expect a U.S. recession later in 2025. Another 15% predict a ...

Intellia Therapeutics, Inc. NTLA is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...